- Home
- ACM vs INCY Comparison
ACM vs INCY Comparison
Compare ACM & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACM
- INCY
- Stock Information
- Founded
- ACM 1980
- INCY 1991
- Country
- ACM United States
- INCY United States
- Employees
- ACM N/A
- INCY N/A
- Industry
- ACM Military/Government/Technical
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- ACM Consumer Discretionary
- INCY Health Care
- Exchange
- ACM Nasdaq
- INCY Nasdaq
- Market Cap
- ACM 12.8B
- INCY 13.4B
- IPO Year
- ACM 2007
- INCY 1993
- Fundamental
- Price
- ACM $92.90
- INCY $68.17
- Analyst Decision
- ACM Strong Buy
- INCY Buy
- Analyst Count
- ACM 8
- INCY 19
- Target Price
- ACM $120.38
- INCY $74.38
- AVG Volume (30 Days)
- ACM 1.1M
- INCY 1.7M
- Earning Date
- ACM 05-05-2025
- INCY 04-29-2025
- Dividend Yield
- ACM 1.10%
- INCY N/A
- EPS Growth
- ACM 685.21
- INCY N/A
- EPS
- ACM 3.50
- INCY 0.15
- Revenue
- ACM $16,219,730,000.00
- INCY $4,241,216,999.00
- Revenue This Year
- ACM $6.71
- INCY $12.23
- Revenue Next Year
- ACM $5.56
- INCY $8.89
- P/E Ratio
- ACM $27.01
- INCY $451.53
- Revenue Growth
- ACM 8.89
- INCY 14.76
- 52 Week Low
- ACM $82.23
- INCY $50.35
- 52 Week High
- ACM $118.56
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- ACM 36.66
- INCY 37.36
- Support Level
- ACM $94.31
- INCY $68.17
- Resistance Level
- ACM $97.99
- INCY $72.81
- Average True Range (ATR)
- ACM 2.88
- INCY 2.31
- MACD
- ACM -0.05
- INCY -0.42
- Stochastic Oscillator
- ACM 14.34
- INCY 13.52
About ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $14.4 billion in sales and $847 million in adjusted operating income in fiscal 2023.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.